Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Comedian and Emmy-nominated actor Kym Whitley opens up about her long journey with weight management. The "Happy Gilmore 2" ...

Texas hairstylist Tim Bo Mack opened up to PEOPLE about his years-long struggle to lose weight. He finally found success ...

Weight-loss wonder drug Mounjaro/Zepbound shrinks breast cancer tumors Date: July 15, 2025 Source: The Endocrine Society Summary: A cutting-edge mouse study reveals that tirzepatide, the dual GLP ...

SAN FRANCISCO — Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women with overweight or obesity, researchers reported at ...

CVS Caremark stops coverage for Eli Lilly's weight loss drug Zepbound, citing high costs, while obesity specialists warn the decision disrupts patient treatment.